# A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.

> **NCT02663752** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **PROCEDURE:** Bone marrow aspirate
- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT02663752
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-30
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-07-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2018-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02663752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02663752, "A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02663752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*